幽门螺杆菌感染对胃黏膜环氧合酶-2表达的影响

目的评估幽门螺杆菌(Hp)感染对慢性胃炎胃黏膜环氧合酶-2(COX-2)表达的影响.方法与10例正常对照者比较,用免疫组化方法半定量检测46例慢性胃炎患者Hp根除治疗前后胃窦黏膜COX-2蛋白的表达,用悉尼分类标准对胃黏膜炎症、活动性和Hp密度进行半定量测定.结果在胃黏膜表面上皮、腺上皮细胞和固有层间质细胞的胞浆中可见COX-2表达.与正常对照者比较,Hp感染胃黏膜的COX-2平均阳性细胞率明显增加[(18.0±14.1)%比(12.3±4.6)%,P＜0.05)];成功根除Hp后的胃黏膜COX-2平均阳性细胞率明显下降[(20.1±13.1)%比(13.8±5.9)%,P＜0.05)];COX-2表达与慢性炎症计分相关(r=0.78,P＜0.05).结论Hp感染导致胃黏膜COX-2表达增加,提示COX-2在Hp相关性胃炎发生中起作用.     

紧密连接蛋白Occludin及ZO-1在根除幽门螺杆菌慢性胃炎组织中的表达

目的观察闭锁蛋白(Occludin)及闭锁小带蛋白(zonula occludens-1,ZO-1)在根除幽门螺杆菌(Helicobacter pylori,H.pylori)慢性胃炎组织中的表达变化,探讨其与患者临床病理及预后的关系。方法采用免疫组织化学法检测H.pylori阴性正常人(25例)、根除H.pylori前后慢性浅表性胃炎(30例)及慢性萎缩性胃炎(30例)患者胃窦黏膜标本中Occludin、ZO-1的蛋白表达。结果 H.pylori阴性的正常人胃黏膜Occludin、ZO-1蛋白表达较H.pylori阳性慢性胃炎患者高,差异有统计学意义(P0.05),H.pylori阳性的慢性浅表性胃炎组织Occludin及ZO-1蛋白表达较慢性萎缩性胃炎增强,差异有统计学意义(P0.05);H.pylori根除治疗后,慢性浅表性胃炎组织中Occludin及ZO-1表达量较治疗前增强(P0.05),慢性萎缩性胃炎组织Occludin、ZO-1表达无明显变化(P0.05);H.pylori未根除患者,Occludin及ZO-1蛋白变化差异无显著性(P0.05)。结论 H.pylori阳性的慢性胃炎患者胃黏膜屏障受损,萎缩发生前根除H.pylori治疗可提高Occludin及ZO-1蛋白表达,进而修复H.pylori引起的胃黏膜损伤。     

胃黏膜癌前病变中p53、p21^ras蛋白表达与幽门螺杆菌感染的关系

目的观察幽门螺杆菌(Helicobacterpylori)感染及根除H.pylori二年后p53、p21ras在二组胃黏膜上皮细胞的表达,探讨H.pylori在胃癌发生、发展中的作用.方法应用免疫组织化学染色、尿素酶快速试验(RUT)、组织学Warthin-Starry染色.198例H.pylori感染患者,慢性胃炎86例,慢性胃炎伴肠化生67例,慢性胃炎伴异型增生45例;对照组为根除H.pylori 2年后共86例,其中慢性胃炎54例,慢性胃炎伴肠化生32例,慢性胃炎伴异型增生10例.全部病例做p53、p21ras免疫组织化学染色.结果 H.pylori感染组p53、p21 ras 阳性表达率15.7%、18.7%,明显高于H.pylori根除组2.3%、7%,差异显著(P＜0.05);慢性胃炎伴肠化病变中,p53、p21ras在H.pylori感染组阳性表达率17.9%、18.4%均高于H.pylori根除组0%、9.4%,差异显著(P＜0.05)慢性胃炎伴异型增生病变中,p53、p21 ras在H.pylori感染组阳性表达率31.1%、40%均高于H.pylori根除组20%、30.4%,差异显著(P＜0.05);H.pylori 感染组p53、p21ras在慢性胃炎,肠化生,异型增生表达水平依次增高p53、p21ras共同表达阳性37例.结论在胃黏膜癌前病变中p53、p21ras 在H.pylori感染组阳性表达率高于H.pylori根除组,差异显著(P＜0.05);在慢性胃炎,肠化生,异型增生p53、p21ras表达水平在增高;p53、p21 ras表达呈正相关;H.pylori感染在胃癌发生、发展过程中起一定作用,p53、p21ras表达可能是H.pylori致癌的作用机理之一.     

幽门螺杆菌阳性消化性溃疡患者胃黏膜核因子κ B、β-防御素-2表达及其与胃窦炎症的关系

目的:检测幽门螺杆菌(H pylori)阳性消化性溃疡(peptic ulcer,PU)患者胃窦黏膜组织学改变和炎症相关基因核因子κB(Nuclear-κB, NF-κB)、人β-防御素-2(human β-denfensin-2, HBD-2)蛋白表达,探讨胃窦黏膜炎症及NF- κB、HBD-2在H pylori相关性PU中的作用及其意义．方法:57例PU患者,其H pylori感染者40例, 非H pylori感染者17例,另设正常对照组8例; 观察各组患者胃窦组织学改变,免疫组化法检测胃窦黏膜NF-κBp65、HBD-2的表达．观察 NF-κBp65、HBD-2的细胞定位情况,用One- Way ANOVA方法比较H pylori感染者与非 H pylori感染者及正常组胃黏膜NF-κBp65、 HBD-2表达量,并对PU不同分期患者胃黏膜 NF-κBp65,HBD-2的表达量进行比较;非参数统计方法分析H pylori感染与PU患者胃窦炎症程度的关系、NF-κBp65、HBD-2表达与胃窦炎症程度的关系及H pylori阳性PU NF- κBp65与HBD-2表达的相关性．结果:PU患者胃窦的炎症程度与H pylori感染程度呈正相关(活动性r=0．374,P<0．01:慢性r=0．333,P<0．05)．在H pylori阳性PU患者 NF-κBp65主要表达于胃黏膜上皮细胞和固有层间质细胞胞核,HBD-2主要表达于胃黏膜表层上皮细胞胞质,二者的表达均较H pylori 阴性组显著增强(6．4±3．28 vs 3．78±2．16, P<0．01;12．96±5．03 vs 4．69±2．05,P<0．01),且均与胃窦黏膜炎症程度具有显著相关性(活动性r=0．744,0．524,P<0．01,慢性r=0．650, 0．606,P<0．01);H pylori阳性PU胃黏膜NF- κBp65表达与HBD-2表达呈正相关关系(r= 0．438,P<0．01)．愈合期和疤痕期PU患者NF- κBp65(4．28±2．11．3．65±2．27)、HBD-2(8．15 ±4．28,6．24±3．71)的表达较活动期者(7．14± 3．24,13．56±5．43)显著降低(P<0．05,P<0．01)．结论:H pylori感染导致胃黏膜NF-κBp65． HBD-2表达增加,胃黏膜炎症程度增强．NF- κB可能通过诱导HBD-2的表达,参与胃窦黏膜炎症反应,从而影响了H Hpylori阳关性PU的病理生理过程．     

根除幽门螺杆菌对胃黏膜萎缩并肠上皮化生以及COX-2、C- met表达的影响

目的研究幽门螺杆菌(helicobacter pylori,Hp)根除前后胃黏膜萎缩和肠上皮化生的变化以及环氧合酶-2(cyclooxygenase-2,COX-2)和肝细胞生长因子受体(C-met)的表达。方法 13例患者均为胃镜加病理确诊有萎缩并肠化生合并HP感染,且成功根除HP感染者。用免疫组化方法半定量检测HP除前后萎缩性胃炎并肠上皮化生COX-2蛋白和C-met蛋白的表达。结果根除前和根除后1个月萎缩程度积分分别为1.3±0.3,1.2±0.7,根除后1个月与根除前比较无显著差异(P>0.05)。萎缩并肠化生胃黏膜C-met平均阳性细胞率从根除前53.2±12.4％下降至根除后48.8±7.7％,比较有显著差异(P=0.034)。胃黏膜COX-2平均阳性细胞率从根除前36.5±14.0％下降至根除后23.3±7.9％,有显著差异(P=0.023)。COX-2表达与C-met表达有一定的相关性(r=0.310,P<0.05)。结论 HP根除短期内不能逆转胃黏膜萎缩,但可使慢性萎缩性胃炎胃黏膜中COX-2和C-met癌基因表达下降。COX-2表达与C-met表达相关。     

不同数量~(13)C-UBT检测值与幽门螺杆菌根除率的关系及影响因素

目的探讨不同数量13C-UBT检测值与幽门螺杆菌(Helicobacter pylori,H.pylori)根除率的关系及影响因素。方法收集2016年1月至2016年8月新疆维吾尔自治区人民医院消化科门诊患者中13C-UBT检测结果阳性并行胃黏膜组织病理切片检查者634例,分析不同数量13C-UBT检测值与H.pylori根除率的关系及影响因素。结果不同数量13C-UBT检测值的H.pylori根除率随13C-UBT检测值的增加而降低(90.0%、89.7%、85.0%、77.2%),onetile组根除率较quartile组根除率高,且差异有统计学意义(90.0%vs 77.2%,P=0.029)。H.pylori根除率与不同数量13C-UBT检测值相关。H.pylori密度与十二指肠溃疡、胃黏膜糜烂、13C-UBT检测值、胃黏膜萎缩、肠化相关。结论不同数量13C-UBT检测值与H.pylori根除率相关,十二指肠溃疡、胃黏膜糜烂、胃黏膜萎缩、肠化及13C-UBT检测值可能影响H.pylori密度的程度。     

闭锁蛋白和闭锁小带蛋白在慢性胃炎组织中的表达和意义

背景:慢性胃炎发病的过程中,生物因子的改变可影响胃黏膜的生理屏障,增加细胞间连接的损伤风险,导致黏膜上皮屏障破坏。目的:探讨闭锁蛋白(occludin)、闭锁小带蛋白-1(ZO-1)在慢性胃炎组织中的表达和意义。方法:选取2014年10月—2017年10月于孝昌县第一人民医院就诊的慢性胃炎患者82例,根据内镜活检病理结果分为慢性非萎缩性胃炎(CNAG)组和慢性萎缩性胃炎(CAG)组,选取同期健康志愿者40名作为正常对照组。采用免疫组化方法检测胃黏膜组织occludin、ZO-1表达。幽门螺杆菌(Hp)阳性患者给予Hp根除治疗,转阴者复查occludin、ZO-1表达。结果:CNAG、CAG组occludin、ZO-1蛋白阳性表达率显著低于正常对照组(P 0. 05); CNAG组occludin、ZO-1蛋白阳性表达率显著高于CAG组(P 0. 05)。CNAG Hp阳性组occludin、ZO-1蛋白阳性表达率显著低于Hp阴性组(P 0. 05); CAG Hp阳性组ZO-1蛋白阳性表达率显著低于Hp阴性组(P 0. 05)。Occludin、ZO-1蛋白表达与胃黏膜炎症活动度呈线性趋势关系(P 0. 05),随着炎症活动度的增加,两者表达显著减弱。CNAG Hp阳性患者转阴后,occludin、ZO-1蛋白阳性表达率较根除治疗前显著升高(P 0. 05)。结论:Occludin、ZO-1在慢性胃炎组织尤其是CAG中表达减弱。两者表达与Hp感染以及胃炎活动度之间存在一定联系。     

萎缩性胃炎患者幽门螺杆菌根除后表皮生长因子及其受体的变化

目的　研究幽门螺杆菌 (Helicobacterpylori,H .pylori)感染对胃黏膜表皮生长因子受体 (epidermalgrowthfactorreceptor ,EGFR)、血清表皮生长因子 (epidermalgrowthfactor,EGF)水平的影响。方法　对 60例H pylori检测阳性的慢性萎缩性胃炎患者进行根除治疗 ,在治疗前及疗程结束 3个月后分别进行胃镜检查 ,并采用免疫组化及放射免疫法测定H pylori根除前后胃黏膜EGFR和血清EGF含量。 3 0例H pylori检测阴性且胃镜检查无明显异常者作为正常对照组。结果　 60例H pylori检测阳性的CAG患者的胃黏膜EGFR阳性率及血清EGF水平均高于正常对照 ,其差异有显著性 (P <0 0 5 ,P <0 0 1)。有 3 1例在根除治疗 3个月后进行了复查 ,其中 2 4例H pylori得到成功根除。 2 4例H pylori得到根除的CAG患者 ,根除后血清EGF水平明显下降 (P <0 0 1) ,而EGFR阳性率无改变 (P >0 0 5 )。结论　H pylori感染引起胃黏膜EGFR阳性率及血清EGF水平增加 ,根除H pylori后血清EGF可恢复至正常水平 ,而胃黏膜EGFR阳性率在短期内没有明显改变     

幽门螺杆菌感染对胃黏膜病理变化的影响

背景：幽门螺杆菌(H．pylori)感染已被公认为慢性胃炎和消化性溃疡的重要危险因素，根除H．pylori能加速消化性溃疡的愈合，但其对胃黏膜病理变化的影响尚有待进一步探索。目的：了解根除H．pylori对慢性胃炎胃黏膜病理变化和癌前状态的影响。方法：采用多中心随机对照临床试验和回顾性队列研究，样本选自胃癌高发区：上海郊区的金山区和奉贤区。共纳入360例经内镜检查证实有H．pylori感染的慢性胃炎伴或不伴十二指肠溃疡患者，随机分为两组。治疗组用三联疗法(质子泵抑制剂或Hz受体阻滞剂加两种抗生素)治疗，对照组单纯慢性胃炎患者予西沙必利、十二指肠溃疡患者予西米替丁治疗。在第1年和第4年末随访胃镜，根据H．pylori是否根除将患者分为两组：H．pylori阳性组和H．pylori阴性组。所有胃黏膜活检标本由两位病理科医师统一复读。结果：至第4年末，有120例患者完成全部随访，其中H．pylori持续根除组54例，阳转组5例；H．pylori持续未根除组45例，阴转组16例。持续根除组第1年随访时，活动性炎症比例减少(P＜O．05)；第4年随访时，慢性炎症和肠化程度以及活动性炎症比例减少(P＜O．05)。持续未根除组第1年随访时，慢性炎症程度增加(P＜O．05)；第4年随访时，慢性炎症和肠化程度以及活动性炎症比例增加(P＜O．05)，萎缩程度较第1年随访时增加(P＜O．05)。结论：根除H．pylori可以减轻慢性胃炎的炎症程度，防止肠化的发生和发展。     

胃黏膜脱垂与慢性胃炎关系探讨

目的研究胃黏膜脱垂(prolapseofgastricmucosa ,GMP)与慢性胃炎的关系。方法选取二组接受胃镜检查的患者①慢性胃炎组,均符合1996年悉尼慢性胃炎诊断标准,并除外胃、十二指肠溃疡性疾病及十二指肠球部变形者。共10 3例,男5 7例,女46例。年龄2 2～74岁,平均年龄48 9岁。②对照组同期接受胃镜检查的患者,未发现胃、十二指肠存在活动性炎症、溃疡等病变表现,亦为10 3名,男60名,女43名。年龄2 0～76岁,平均年龄47 3岁。结果①共69例( 3 3 .5 % )存在GMP ,其中慢性胃炎患者及对照组中分别为43例( 4 1.7% )及2 6例( 2 5 .2 % ) ,慢性胃炎组中GMP检出率显著高于对照组(P <0 .0 5 )。②GMP在各年龄组,男女间发病率无显著性差异(P >0 .0 5 )。③GMP患者中Helicobecterpylori检测阳性率( 10 7% )显著低于GMP阴性患者H .pylori检出率( 2 6.2 % ) (P <0 .0 5 )。④43例伴GMP的慢性胃炎中胃窦条状红斑( 3 0 .2 % )、食管炎( 16.3 % )均高于60例不伴GMP中相应比例( 10 .0 % ,P <0 .0 1;3 .3 % ,P <0 .1)。结论GMP与慢性胃炎相关,胃窦条状红斑为特征性表现,GMP患者易合并食管炎;GMP发生与性别年龄无关;GMP患者H .pylori感染率较低。     

Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection

OBJECTIVE: Helicobacter pylori (H. pylori) causes chronic gastritis. The inducible prostaglandin synthetase cyclooxygenase 2 (COX-2) plays an important role in inflammatory conditions. We hypothesized that H. pylori-associated chronic gastritis would express COX-2 protein. Our aim was to evaluate the effect of eradication of H. pylori infection on COX-2 expression in the antral mucosa of patients before and after antibiotic therapy. METHODS: Tissues were obtained from patients with non-ulcer dyspepia undergoing H. pylori eradication. Ten patients with proven H. pylori infection and subsequent successful eradication were studied. Three biopsies of antral mucosa were evaluated before and after H. pylori eradication. The amount of acute and chronic inflammation was quantitated. Immunohistochemical staining for COX-2 was expressed as a percentage of the total number of cells and correlated with the degree of chronic inflammation. RESULTS: Specific immunostaining for COX-2 was observed in antral mucosa of patients infected with H. pylori. Patchy cytoplasmic staining was seen in surface epithelial cells and strong cytoplasmic staining for COX-2 was seen in parietal cells. Spotty cytoplasmic staining for COX-2 was also seen in lamina propria plasma cells, as well as there being macrophages present in the germinal centers of lymphoid aggregates. COX-2 expression could be detected both before and after eradication of H. pylori. The mean percentage of cells staining for COX-2 was significantly higher in H. pylori-infected mucosa, compared with mucosa after successful H. pylori eradication (33.4% +/- 5.4 vs 18.9% +/- 3.3, p = 0.038). COX-2 immunostaining correlated best with the chronic inflammation score (r2 = 0.78, p < 0.001). There was a strong correlation for those subjects who were H. pylori infected, as well as for those who had successful H. pylori eradication. CONCLUSIONS: H. pylori associated acute and chronic antral inflammation was associated with immunohistochemical detection of COX-2 protein in epithelial cells, in addition to associated mononuclear cells and parietal cells. Expression was reduced, but not eliminated, in the epithelium after successful eradication of H. pylori. Despite the reduction in COX-2 expression after H. pylori eradication, expression of COX-2 in epithelial cells remained and strongly correlated with the extent of the chronic inflammatory cell infiltrate. The clinical implications of H. pylori-associated induction of COX-2 expression for patients on selective COX-2 inhibitors, in addition to the role of COX-2 in gastric carcinogenesis, deserve further study.     

Anti-Helicobacterpylori therapy followed by celecoxib on progression of gastric precancerous lesions

AIM： To evaluate whether celecoxib, a selective cyclooxygenase 2 （COX-2） inhibitor, could reduce the severity of gastric precancerous lesions following Hel/cobacter pylori （H pylorl） eradication. METHODS： H pylori-eradicated patients with gastric precancerous lesions randomly received either celecoxib （n = 30） or placebo （n = 30） for up to 3 mo. COX-2 expression and activity was determined by immunostaining and prostaglandin E2 （PGE2） assay, cell proliferation by Ki-67 immunostaining, apoptosis by TUNEL staining and angiogenesis by microvascular density （MVD） assay using CD31 staining.RESULTS： COX-2 protein expression was significantly increased in gastric precancerous lesions （atrophy, intestinal metaplasia and dysplasia, respectively） compared with chronic gastritis, and was concomitant with an increase in cell proliferation and angiogenesis. A significant improvement in precancerous lesions was observed in patients who received celecoxib compared with those who received placebo （P 〈 0.001）. Of these three changes, 84.6% of sites with dysplasia regressed in patients treated with celecoxib （P = 0.002） compared with 60% in the placebo group, suggesting that celecoxib was effective on the regression of dysplasia. COX-2 protein expression （P 〈 0.001） and COX-2 activity （P 〈 0.001） in the gastric tissues were consistently lower in celecoxib-treated patients compared with the placebo-treated subjects. Moreover, it was also shown that celecoxib suppressed cell proliferation （P 〈 0.01）, induced cell apoptosis （P 〈 0.01） and inhibited angiogenesis with decreased MVD （P 〈 0.001）. However, all of these effects were not seen in placebo-treated subjects. Furthermore, COX-2 inhibition resulted in the up-regulation of PPARy expression, a protective molecule with anti-neoplastic effects. CONCLUSION： H pylori eradication therapy followed by celecoxib treatment improves gastric precancerous lesions by inhibiting COX-2 activity, inducing apoptosis, and suppressing cell proliferation and angiogenesis.     

根除Hp前后胃窦粘膜COX-2表达的变化

目的检测胃窦粘膜在根除Hp前后环氧化酶-2(Cyclooxygenase-2,COX-2)表达水平的变化,探讨COX-2表达与急、慢性炎症的关系.方法对我院1999.6-2000.3胃镜诊断为慢性胃炎、胃粘膜活组织尿素酶试验和14C尿素呼气试验均证实Hp阳性的14例住院病人,在根除Hp前后取胃粘膜活检组织,HE染色显示组织结构和炎性细胞浸润情况,用免疫组织化学方法(SP法)显示COX-2表达情况.结果感染区域的胃窦上皮细胞和相应的壁细胞、单核细胞均可检测到COX-2的阳性表达,与根除Hp后比较,COX-2的表达明显减少而不完全消失(P＜0.005),COX-2阳性表达率与胃粘膜的急性炎症程度无关,而与慢性炎性细胞浸润密切相关(r=0.74 P＜0.05).结论COX-2的高表达可能是Hp相关性胃炎发生的重要机制.     

幽门螺杆菌感染胃黏膜病变基因表达和细胞生物学行为

目的　研究幽门螺杆菌(Helicobacterpylori,Hp)感染胃黏膜病变的多基因表达和细胞生物学行为。方法　327例患者经胃镜及手术的胃黏膜病变标本,应用免疫组化染色法,检测p53、p16、bcl-2和环氧合酶同工酶-2(COX-2)蛋白的表达。Hp感染由快速尿素酶试验结合组织学检查/     

Effects of Helicobacter pylori Infection on gastric mucin expression

AIMS: This study was performed to determine the gastric distributions of MUC5AC and MUC6 depending on Helicobacter pylori (H. pylori) infection, and to evaluate whether the expressions of MUC5 and MUC6 change in H. pylori-associated gastroduodenal diseases. In addition, MUC5AC and MUC6 expressional changes were investigated before and after H. pylori eradication. METHODS: In the 224 individuals (136 H. pylori-positive and 88 H. pylori-negative) who came from control (N=48), duodenal ulcer (N=35), benign gastric ulcer (N=61), dysplasia plus stomach cancer (N=80) groups, MUC5AC and MUC6 expressions were determined by immunohistochemical staining in the antrum and body, respectively. This staining for MUC5AC and MUC6 were reperformed in 113 of the 136 H. pylori-positive patients after successful H. pylori eradication by proton pump inhibitor-based triple therapy. RESULTS: (1) No difference was found between the H. pylori-positive and negative groups in terms of MUC5AC expression. In contrast, MUC6 expression was significantly lower in the H. pylori-positive group than in the H. pylori-negative group in the gastric body. Moreover, reduced MUC6 expression increased to the H. pylori-negative level after eradication. (2) Expressions of MUC5AC and MUC6 were significantly lower in the dysplasia plus cancer group than those of control in case of H. pylori positive. Similarly, MUC5AC and MUC6 expressions were significantly lower in the presence of atrophic gastritis with intestinal metaplasia in case of H. pylori positive. (3) Aberrant expressions of MUC6 in foveolar cells were observed in both antrum (11.3%) and body (5.3%) only in the H. pylori-positive group, but this reverted to normal after H. pylori eradication. CONCLUSION: These results suggest that H. pylori infection causes alterations of mucin expression, closely related with the development of gastric atrophy with intestinal metaplasia, probably contributing to carcinogenesis.     

In Dyspeptic Patients without Gastric Phase III of the Migrating Motor Complex,Helicobacter pylori Eradication Produces no Short-term Changes in Interdigestive Motility Pattern

Background: The relationship between Helicobacter pylori infection and interdigestive gastroduodenal motility in functional dyspepsia is still uncertain. Recent data from a large series documented that in dyspeptic patients without gastric phase III of the interdigestive migrating motor complex (MMC), the prevalence of bacterial infection was significantly higher. Since most H. pylori-positive dyspeptic patients have coexisting chronic gastritis, whether or not dyspepsia per se rather than bacterial colonization or chronic inflammation of the gastric mucosa may account for the observed interdigestive motility pattern is unknown. Our aim was to compare the interdigestive gastroduodenal motility pattern and dyspeptic symptoms before and 1 month after bacterial eradication in 20 H. pylori-positive dyspeptic subjects with chronic non-atrophic gastritis and without gastric phase III of the MMC, who were randomly allocated to receive eradication treatment (n = 10) or not (n = 10). Methods: Upper GI endoscopy with duplicate biopsies in antrum and corpus, 240-min interdigestive gastroduodenal manometric recording and symptoms assessment were performed before and 1 month after the treatments; bacterial eradication was confirmed by 13C-urea breath test. Results: After H. pylori eradication, neither in the incidence of antral and duodenal phase III of MMC nor in the phase II motility index values were any changes observed. Symptomatic improvement was recorded in both groups, with no significant differences between eradicated patients and controls. Conclusions: In dyspeptic patients with chronic non-atrophic gastritis and without gastric phase III of MMC, H. pylori eradication influences neither the interdigestive motility pattern nor the symptoms in the short-term period.     

In dyspeptic patients without gastric phase III of the migrating motor complex, Helicobacter pylori eradication produces no short-term changes in interdigestive motility pattern

BACKGROUND: The relationship between Helicobacter pylori infection and interdigestive gastroduodenal motility in functional dyspepsia is still uncertain. Recent data from a large series documented that in dyspeptic patients without gastric phase III of the interdigestive migrating motor complex (MMC), the prevalence of bacterial infection was significantly higher. Since most H. pylori-positive dyspeptic patients have coexisting chronic gastritis, whether or not dyspepsia per se rather than bacterial colonization or chronic inflammation of the gastric mucosa may account for the observed interdigestive motility pattern is unknown. Our aim was to compare the interdigestive gastroduodenal motility pattern and dyspeptic symptoms before and 1 month after bacterial eradication in 20 H. pylori-positive dyspeptic subjects with chronic non-atrophic gastritis and without gastric phase III of the MMC, who were randomly allocated to receive eradication treatment (n = 10) or not (n = 10). METHODS: Upper GI endoscopy with duplicate biopsies in antrum and corpus, 240-min interdigestive gastroduodenal manometric recording and symptoms assessment were performed before and 1 month after the treatments; bacterial eradication was confirmed by 13C-urea breath test. RESULTS: After H. pylori eradication, neither in the incidence of antral and duodenal phase III of MMC nor in the phase II motility index values were any changes observed. Symptomatic improvement was recorded in both groups, with no significant differences between eradicated patients and controls. CONCLUSIONS: In dyspeptic patients with chronic non-atrophic gastritis and without gastric phase III of MMC, H. pylori eradication influences neither the interdigestive motility pattern nor the symptoms in the short-term period.     

The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer

Epidemiologically, the association between chronic Helicobacter pylori infection and development of gastric cancer is well established. Although the possibility of preventing gastric cancer by eradicating H. pylori infection was recently investigated by several research groups, the results remain controversial. The aim of this study was to determine whether the eradication of H. pylori infection would reduce the incidence of gastric cancer. In total, 304 patients with persistent H. pylori infection and 404 patients with H. pylori infection eradicated were examined annually for gastric cancer by endoscopy. Over an average of 3.1 years for the first group and 3.2 years for the second group, 13 and 6 patients, respectively, were diagnosed as having new gastric cancer. The cumulative incidence of gastric cancer was statistically different between the groups (P=0.019; log-rank test). The hazard ratio of H. pylori eradication was 0.335 by Cox proportional hazards model (P=0.047). Differentiated gastric cancer was found in 11 patients in the persistent infection group and 3 patients in the eradicated group. The incidence of differentiated cancer was significantly different (P=0.017) between the groups, but not for undifferentiated cancer (P=0.847). The results of the current study suggest that the eradication of H. pylori infection reduces the incidence of gastric cancer.